Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
ALK inhibitor
DRUG CLASS:
ALK inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
NVL-655 (1)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
ZG0418 (0)
TSR-011 (0)
XZP-3621 (0)
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
NVL-655 (1)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
ZG0418 (0)
TSR-011 (0)
XZP-3621 (0)
›
Associations
(944)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
alectinib
Sensitive: A1 - Approval
alectinib
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ensartinib
Sensitive: A1 - Approval
ensartinib
Sensitive
:
A1
ensartinib
Sensitive: A1 - Approval
ensartinib
Sensitive
:
A1
NTRK3 fusion
Solid Tumor
NTRK3 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
repotrectinib
Sensitive: A1 - Approval
repotrectinib
Sensitive
:
A1
repotrectinib
Sensitive: A1 - Approval
repotrectinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ceritinib
Sensitive: A1 - Approval
ceritinib
Sensitive
:
A1
ceritinib
Sensitive: A1 - Approval
ceritinib
Sensitive
:
A1
No biomarker
Solid Tumor
No biomarker
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK2 fusion
Solid Tumor
NTRK2 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
iruplinalkib
Sensitive: A1 - Approval
iruplinalkib
Sensitive
:
A1
iruplinalkib
Sensitive: A1 - Approval
iruplinalkib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Small Intestinal Carcinoma
NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
NTRK2 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ROS1 rearrangement
Non Small Cell Lung Cancer
ROS1 rearrangement
Non Small Cell Lung Cancer
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ROS1 rearrangement
Non Small Cell Lung Cancer
ROS1 rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login